Xia Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xia Chen has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Jing Jie
Department of Clinical Laboratory, Affiliated Hospital 2 of Nantong University, Nantong, China
2 shared publicationsLongXun Zhu
Department of Pharmacy, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, People’s Republic of China
2 shared publicationsNan Sheng
Department of Clinical Laboratory, Affiliated Hospital 2 of Nantong University, Nantong, China
2 shared publicationsPanFeng Feng
Department of Pharmacy, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, People’s Republic of China
2 shared publicationsPengXiang Yang
Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical Science, Harbin Medical University, Harbin, China
2 shared publications- Xiangfan Chen
Department of Pharmacy, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 7 July 2025
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (7) , 1-7
Correction: Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway
- 7 July 2025
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (7) , 1-7
Open AccessCorrection: Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway
- Open Access
- 22 July 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-33
Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges
Rheumatoid arthritis (RA) is an autoimmune disease with multifactorial etiology and intricate pathogenesis. In RA, repeated monotherapy is frequently associated with inadequate efficacy, drug resistance, and severe side effects. Therefore, a shift has occurred in clinical practice toward combination therapy. However, conventional combination therapy encounters several hindrances, including low selectivity to arthritic joints, short half-lives, and varying pharmacokinetics among coupled drugs. Emerging nanotechnology offers an incomparable opportunity for developing advanced combination therapy against RA. First, it allows for co-delivering multiple drugs with augmented physicochemical properties, targeted delivery capabilities, and controlled release profiles. Second, it enables therapeutic nanomaterials development, thereby expanding combination regimens to include multifunctional nanomedicines. Lastly, it facilitates the construction of all-in-one nanoplatforms assembled with multiple modalities, such as phototherapy, sonodynamic therapy, and imaging. Thus, nanotechnology offers a promising solution to the current bottleneck in both RA treatment and diagnosis. This review summarizes the rationale, advantages, and recent advances in nano-empowered combination therapy for RA. It also discusses safety considerations, drug–drug interactions, and the potential for clinical translation. Additionally, it provides design tips and an outlook on future developments in nano-empowered combination therapy. The objective of this review is to achieve a comprehensive understanding of the mechanisms underlying combination therapy for RA and unlock the maximum potential of nanotechnology, thereby facilitating the smooth transition of research findings from the laboratory to clinical practice.
- 22 July 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-33
Open AccessNanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges
Rheumatoid arthritis (RA) is an autoimmune disease with multifactorial etiology and intricate pathogenesis. In RA, repeated monotherapy is frequently associated with inadequate efficacy, drug resistance, and severe side effects. Therefore, a shift has occurred in clinical practice toward combination therapy. However, conventional combination therapy encounters several hindrances, including low selectivity to arthritic joints, short half-lives, and varying pharmacokinetics among coupled drugs. Emerging nanotechnology offers an incomparable opportunity for developing advanced combination therapy against RA. First, it allows for co-delivering multiple drugs with augmented physicochemical properties, targeted delivery capabilities, and controlled release profiles. Second, it enables therapeutic nanomaterials development, thereby expanding combination regimens to include multifunctional nanomedicines. Lastly, it facilitates the construction of all-in-one nanoplatforms assembled with multiple modalities, such as phototherapy, sonodynamic therapy, and imaging. Thus, nanotechnology offers a promising solution to the current bottleneck in both RA treatment and diagnosis. This review summarizes the rationale, advantages, and recent advances in nano-empowered combination therapy for RA. It also discusses safety considerations, drug–drug interactions, and the potential for clinical translation. Additionally, it provides design tips and an outlook on future developments in nano-empowered combination therapy. The objective of this review is to achieve a comprehensive understanding of the mechanisms underlying combination therapy for RA and unlock the maximum potential of nanotechnology, thereby facilitating the smooth transition of research findings from the laboratory to clinical practice.
- Open Access
- 5 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0296508
Meta-analysis of the efficacy and safety of Ginkgolide Meglumine Injection combined with Butylphthalide in the treatment of Acute Ischemic Stroke
Objective: To evaluate the efficacy and safety of Ginkgolide Meglumine Injection (GMI) combined with Butylphthalide in the treatment of Acute Ischemic Stroke (AIS), and provide reference for rational clinical medication. Methods: PubMed, Embase, Web of science, CNKI, Wanfang, VIP and other databases were searched for published studies on the treatment of AIS with GMI combined with Butylphthalide in both Chinese and English. The search period was from the establishment of the database to July 2023. The included studies that met the inclusion criteria were analyzed using RevMan 5.3 software for Meta-analysis. Results: A total of 25 studies involving 2362 patients (experimental group = 1182, control group = 1180) were included. The results of meta-analysis showed that the overall effective rate of the experimental group was significantly higher than that of the control group [RR = 1.21, 95% CI (1.16, 1.26), P< 0.00001]. In addition, compared with the control group, the experimental group showed significant improvement in NIHSS score [SMD = -1.59, % CI (-2.00–1.18), P< 0.00001] and ADL score [SMD = 2.12, 95% CI (1.52, -2.72), P 0.05]. Conclusion: GMI combined with Butylphthalide shows good clinical application effects and good safety in the treatment of AIS. However, more large-sample, multicenter, randomized controlled are needed to confirm these findings.
- 5 January 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (1) , e0296508
Open AccessMeta-analysis of the efficacy and safety of Ginkgolide Meglumine Injection combined with Butylphthalide in the treatment of Acute Ischemic Stroke
Objective: To evaluate the efficacy and safety of Ginkgolide Meglumine Injection (GMI) combined with Butylphthalide in the treatment of Acute Ischemic Stroke (AIS), and provide reference for rational clinical medication. Methods: PubMed, Embase, Web of science, CNKI, Wanfang, VIP and other databases were searched for published studies on the treatment of AIS with GMI combined with Butylphthalide in both Chinese and English. The search period was from the establishment of the database to July 2023. The included studies that met the inclusion criteria were analyzed using RevMan 5.3 software for Meta-analysis. Results: A total of 25 studies involving 2362 patients (experimental group = 1182, control group = 1180) were included. The results of meta-analysis showed that the overall effective rate of the experimental group was significantly higher than that of the control group [RR = 1.21, 95% CI (1.16, 1.26), P< 0.00001]. In addition, compared with the control group, the experimental group showed significant improvement in NIHSS score [SMD = -1.59, % CI (-2.00–1.18), P< 0.00001] and ADL score [SMD = 2.12, 95% CI (1.52, -2.72), P 0.05]. Conclusion: GMI combined with Butylphthalide shows good clinical application effects and good safety in the treatment of AIS. However, more large-sample, multicenter, randomized controlled are needed to confirm these findings.
- 12 August 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (7) , 3587-3598
Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway
Colorectal cancer (CRC) is the leading cause of cancer deaths worldwide, wherein distant metastasis is the main reason for death. The non-psychoactive phytocannabinoid cannabidiol (CBD) effectively induces the apoptosis of CRC cells. We investigated the role of CBD in the migration and metastasis of CRC cells. CBD significantly inhibited proliferation, migration, and invasion of colon cancer cells in a dose- or time-dependent manner. CBD could also inhibit epithelial–mesenchymal transition (EMT) by upregulating epithelial markers such as E-cadherin and downregulating mesenchymal markers such as N-cadherin, Snail, Vimentin, and HIF-1α. CBD could suppress the activation of the Wnt/β-catenin signaling pathway, inhibit the expression of β-catenin target genes such as APC and CK1, and increase the expression of Axin1. Compared to the control group, the volume and weight of orthotopic xenograft tumors significantly decreased after the CBD treatment. The results demonstrated that CBD inhibits invasion and metastasis in CRC cells. This was the first study elucidating the underlying molecular mechanism of CBD in inhibiting EMT and metastasis via the Wnt/β-catenin signaling pathway in CRC cells. The molecular mechanism by which CBD inhibits EMT and metastasis of CRC cells was shown to be through the Wnt/β-catenin signaling pathway for the first time.
- 12 August 2022
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (7) , 3587-3598
Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway
Colorectal cancer (CRC) is the leading cause of cancer deaths worldwide, wherein distant metastasis is the main reason for death. The non-psychoactive phytocannabinoid cannabidiol (CBD) effectively induces the apoptosis of CRC cells. We investigated the role of CBD in the migration and metastasis of CRC cells. CBD significantly inhibited proliferation, migration, and invasion of colon cancer cells in a dose- or time-dependent manner. CBD could also inhibit epithelial–mesenchymal transition (EMT) by upregulating epithelial markers such as E-cadherin and downregulating mesenchymal markers such as N-cadherin, Snail, Vimentin, and HIF-1α. CBD could suppress the activation of the Wnt/β-catenin signaling pathway, inhibit the expression of β-catenin target genes such as APC and CK1, and increase the expression of Axin1. Compared to the control group, the volume and weight of orthotopic xenograft tumors significantly decreased after the CBD treatment. The results demonstrated that CBD inhibits invasion and metastasis in CRC cells. This was the first study elucidating the underlying molecular mechanism of CBD in inhibiting EMT and metastasis via the Wnt/β-catenin signaling pathway in CRC cells. The molecular mechanism by which CBD inhibits EMT and metastasis of CRC cells was shown to be through the Wnt/β-catenin signaling pathway for the first time.
- 1 January 2022
- Published by AEPress, s.r.o. in General Physiology and Biophysics
- Vol. 41 (06) , 511-521
TGFβ1 induces myofibroblast transdifferentiation via increasing Smad-mediated RhoGDI-RhoGTPase signaling
TGFβ1 induces myofibroblast transdifferentiation via increasing Smad-mediated RhoGDI-RhoGTPase signaling
- 1 January 2022
- Published by AEPress, s.r.o. in General Physiology and Biophysics
- Vol. 41 (06) , 511-521
TGFβ1 induces myofibroblast transdifferentiation via increasing Smad-mediated RhoGDI-RhoGTPase signaling
TGFβ1 induces myofibroblast transdifferentiation via increasing Smad-mediated RhoGDI-RhoGTPase signaling